Ferroptosis: the vulnerability within a cancer monster

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Treatment-resistant cancers, like neuroendocrine prostate cancer (NEPC), present significant therapeutic challenges.
• The tumor suppressor gene RB1 is frequently lost in NEPC, impacting cancer cell behavior.
• Understanding the molecular mechanisms underlying NEPC resistance is crucial for developing effective treatments.

Purpose of the Study:

• To investigate how the loss of RB1 influences cancer cell sensitivity to ferroptosis.
• To explore the role of ACSL4 (acyl-CoA synthetase long-chain family member 4) in RB1-deficient NEPC.
• To identify potential therapeutic vulnerabilities in RB1-loss NEPC.

Main Methods:

• Analysis of RB1 status in NEPC tumors.
• Assessing the expression levels of ACSL4 and GPX4 (glutathione peroxidase 4) in relation to RB1 loss.
• Investigating the effects of ferroptosis inducers and GPX4 inhibitors on RB1-deficient cancer cells.

Main Results:

• RB1 loss in NEPC leads to elevated levels of ACSL4, a key enzyme in lipid peroxidation.
• Elevated ACSL4 sensitizes RB1-deficient cells to ferroptosis.
• The antioxidant enzyme GPX4 normally suppresses ferroptosis in cancer cells, but its inhibition can trigger ferroptosis in RB1-deficient cells.

Conclusions:

• RB1-deficient NEPC cells exhibit an inherent vulnerability to ferroptosis due to increased ACSL4.
• Targeting the ferroptosis pathway, particularly by inhibiting GPX4, presents a promising therapeutic strategy for RB1-deficient, treatment-resistant prostate cancer.